Immunovant Director Atul Pande's Stock Transactions and Option Exercise

This Form 4 filing reports multiple transactions by Immunovant, Inc. director Atul Pande on June 26, 2026. Pande exercised stock options to purchase 1,500 shares at $8.43 per share, then immediately sold the same 1,500 shares at $38.01 per share, resulting in significant profit. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, Pande directly owns 116,731 shares and holds 20,000 additional shares indirectly through a trust. The director also holds 68,181 stock options following the exercise. The filing demonstrates substantial insider trading activity with a notable price difference between the option exercise price and market sale price, indicating profitable transactions by the director.